이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jiangsu Nhwa Pharmaceutical 관리

관리 기준 확인 3/4

Jiangsu Nhwa Pharmaceutical's CEO는 Jiaquan Sun, May2013 에 임명되었습니다 의 임기는 11.08 년입니다. 는 CN¥ 17.10M 가치에 해당하는 회사 주식의 0.071% 직접 소유합니다. 17.10M. 경영진과 이사회의 평균 재임 기간은 각각 11.1 년과 17.2 년입니다.

주요 정보

Jiaquan Sun

최고 경영자

CN¥4.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	11.2yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	11.2yrs
이사회 평균 재임 기간	17.3yrs

최근 관리 업데이트

Recent updates

CEO

Jiaquan Sun (48 yo)

11.2yrs

테뉴어

CN¥4,800,000

보상

Mr. Jiaquan Sun has been General Manager at Jiangsu Nhwa Pharmaceutical Co., Ltd. since May 31, 2013 and has been its Non-Independent Director since April 1, 2019. Mr. Sun serves as General Manager of Jian...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jiaquan Sun	GM & Non-Independent Director	11.2yrs	CN¥4.80m	0.071% CN¥ 16.9m
Gangsheng Li	Chief Financial Officer	1.8yrs	CN¥633.60k	데이터 없음
Qing Fu	Deputy GM & Non-Independent Director	11.2yrs	CN¥200.00k	3.96% CN¥ 947.9m
Zengliang Chen	Deputy GM & Non-Independent Director	11.2yrs	CN¥200.00k	3.96% CN¥ 947.9m
Ziliang Yang	Deputy GM & Non-Independent Director	11.2yrs	CN¥200.00k	3.72% CN¥ 891.0m
Bao Zhou Duan	Deputy GM & Secretary	11.2yrs	CN¥413.70k	0.0053% CN¥ 1.3m

11.2yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 002262 의 관리팀은 노련하고 경험 (평균 재직 기간 11.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jiaquan Sun	GM & Non-Independent Director	14.2yrs	CN¥4.80m	0.071% CN¥ 16.9m
Qing Fu	Deputy GM & Non-Independent Director	17.3yrs	CN¥200.00k	3.96% CN¥ 947.9m
Zengliang Chen	Deputy GM & Non-Independent Director	17.3yrs	CN¥200.00k	3.96% CN¥ 947.9m
Ziliang Yang	Deputy GM & Non-Independent Director	17.3yrs	CN¥200.00k	3.72% CN¥ 891.0m
Pengsheng Sun	Non-Independent Chairman of the Board	17.3yrs	CN¥250.00k	4.91% CN¥ 1.2b
Guangji Wang	Independent Director	5.3yrs	CN¥50.00k	데이터 없음
Yu Lan Li	Independent Director	2.3yrs	CN¥50.00k	데이터 없음
Fengshou Wang	Chairman of the Supervisory Board	17.3yrs	데이터 없음	데이터 없음
Xinglei Jia	Member of the Supervisory Board	17.3yrs	데이터 없음	데이터 없음
Xiao Chen Qian	Employee Representative Member of Supervisory Board	17.3yrs	데이터 없음	데이터 없음
Xiaoxing Yin	Independent Director	2.3yrs	CN¥50.00k	데이터 없음
Guoxiang Chen	Independent Director	2.3yrs	CN¥50.00k	데이터 없음

17.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 002262 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 17.2 년).

Jiangsu Nhwa Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2024 Results on Jul 31, 2024

Now 21% overvalued

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.89 in FY 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.30 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.25 in 2Q 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Full year 2022 earnings released: EPS: CN¥0.89 (vs CN¥0.79 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: EPS: CN¥0.79 (vs CN¥0.72 in FY 2020)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Revenue beats expectations

New 90-day low: CN¥14.10

Investor sentiment deteriorated over the past week

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령